Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States.

BACKGROUND The optimal community-level approach to control pandemic influenza is unknown. METHODS We estimated the health outcomes and costs of combinations of 4 social distancing strategies and 2 antiviral medication strategies to mitigate an influenza pandemic for a demographically typical US community. We used a social network, agent-based model to estimate strategy effectiveness and an economic model to estimate health resource use and costs. We used data from the literature to estimate clinical outcomes and health care utilization. RESULTS At 1% influenza mortality, moderate infectivity (R(o) of 2.1 or greater), and 60% population compliance, the preferred strategy is adult and child social distancing, school closure, and antiviral treatment and prophylaxis. This strategy reduces the prevalence of cases in the population from 35% to 10%, averts 2480 cases per 10,000 population, costs $2700 per case averted, and costs $31,300 per quality-adjusted life-year gained, compared with the same strategy without school closure. The addition of school closure to adult and child social distancing and antiviral treatment and prophylaxis, if available, is not cost-effective for viral strains with low infectivity (R(o) of 1.6 and below) and low case fatality rates (below 1%). High population compliance lowers costs to society substantially when the pandemic strain is severe (R(o) of 2.1 or greater). CONCLUSIONS Multilayered mitigation strategies that include adult and child social distancing, use of antivirals, and school closure are cost-effective for a moderate to severe pandemic. Choice of strategy should be driven by the severity of the pandemic, as defined by the case fatality rate and infectivity.

[1]  M. Meltzer,et al.  The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.

[2]  Walter E. Beyeler,et al.  Effective, Robust Design of Community Mitigation for Pandemic Influenza: A Systematic Examination of Proposed US Guidance , 2008, PloS one.

[3]  Laura M. Glass,et al.  Targeted Social Distancing Designs for Pandemic Influenza , 2006, Emerging infectious diseases.

[4]  Documentation for the 2003-04 Schools and Staffing Survey. NCES 2007-337. , 2007 .

[5]  Kristi L Koenig,et al.  State of research in high-consequence hospital surge capacity. , 2006, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[6]  D. Owens,et al.  Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. , 2009 .

[7]  Case Reports Update: swine influenza A (H1N1) infections--California and Texas, April 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[8]  Markus Schwehm,et al.  Influenza pandemic intervention planning using InfluSim: pharmaceutical and non- pharmaceutical interventions , 2007, BMC infectious diseases.

[9]  J. Farrar,et al.  Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series , 2008, The Lancet.

[10]  D. Fleming,et al.  Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients , 2012, PharmacoEconomics.

[11]  P. Ward,et al.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. , 2000, JAMA.

[12]  Derek DeLia,et al.  Annual bed statistics give a misleading picture of hospital surge capacity. , 2006, Annals of emergency medicine.

[13]  Arunkumar Pennathur,et al.  Modeling hospital response to mild and severe influenza pandemic scenarios under normal and expanded capacities. , 2007, Military medicine.

[14]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[15]  J. Mauskopf,et al.  Cost Effectiveness of Zanamivir for the Treatment of Influenza in a High Risk Population in Australia , 2000, PharmacoEconomics.

[16]  V Demicheli,et al.  Neuraminidase inhibitors for preventing and treating influenza in healthy adults. , 2011, The Cochrane database of systematic reviews.

[17]  P. Ward,et al.  Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. , 2004, The Journal of infectious diseases.

[18]  M Elizabeth Halloran,et al.  Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups , 2006, Journal of the Royal Statistical Society. Series C, Applied statistics.

[19]  J. A. Navarro,et al.  Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. , 2007, JAMA.

[20]  Neil M. Ferguson,et al.  The effect of public health measures on the 1918 influenza pandemic in U.S. cities , 2007, Proceedings of the National Academy of Sciences.

[21]  A. Usa,et al.  Update: swine influenza A (H1N1) infections--California and Texas, April 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[22]  R. P. Kandle,et al.  Occupational Outlook Handbook , 1952 .

[23]  Carmen DeNavas-Walt,et al.  Income, Poverty, and Health Insurance Coverage in the United States: 2004 , 2006 .

[24]  P. Ward,et al.  Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. , 2003, Archives of internal medicine.

[25]  W. Edmunds,et al.  Precautionary Behavior in Response to Perceived Threat of Pandemic Influenza , 2007, Emerging infectious diseases.

[26]  R. Klein,et al.  The Beaver Dam Health Outcomes study , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  M. Brandeau,et al.  Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies. , 2006, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[28]  C. Bridges,et al.  The annual impact of seasonal influenza in the US: measuring disease burden and costs. , 2007, Vaccine.

[29]  Larisa V. Gubareva,et al.  Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 , 2008, Antimicrobial Agents and Chemotherapy.

[30]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[31]  Victoria J. Davey,et al.  Rescinding Community Mitigation Strategies in an Influenza Pandemic , 2007, Emerging infectious diseases.

[32]  J. Brundage Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness , 2006, The Lancet Infectious Diseases.

[33]  Gerard F Anderson,et al.  Health spending in OECD countries in 2004: an update. , 2007, Health affairs.

[34]  J. Norwood,et al.  Occupational outlook handbook , 1990 .

[35]  S. Ear Swine flu , 2012, Politics and the Life Sciences.

[36]  D. Wagener,et al.  State Plans for Containment of Pandemic Influenza , 2006, Emerging infectious diseases.

[37]  E. Lyons,et al.  Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings , 2009, Science.

[38]  M. Lipsitch,et al.  Public health interventions and epidemic intensity during the 1918 influenza pandemic , 2007, Proceedings of the National Academy of Sciences.

[39]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[41]  D. Bravata,et al.  Systematic Review: Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza , 2009, Annals of Internal Medicine.

[42]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[43]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[44]  Brian Chin,et al.  Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis , 2006, The Lancet.